Primary gastrointestinal stromal tumor of the liver in an anorectal melanoma survivor: A case report
- Authors:
- Yung‑Yeh Su
- Nai‑Jung Chiang
- Chun‑Chieh Wu
- Li‑Tzong Chen
View Affiliations
Affiliations: Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C., National Institute of Cancer Research, National Health Research Institutes, Tainan 704, Taiwan, R.O.C., Department of Pathology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan, R.O.C.
- Published online on: August 4, 2015 https://doi.org/10.3892/ol.2015.3561
-
Pages:
2366-2370
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The majority of gastrointestinal stromal tumors (GISTs) arise in the stomach and small intestine; primary GIST of the liver is extremely rare. GISTs share specific immunohistological features with melanoma, therefore, determining a definitive diagnosis can be difficult. However, electron microscopy can be used to aid the differential diagnosis of GIST. The present study reports the first case of a KIT/platelet‑derived growth factor receptor α (PDGFRA) wild‑type, primary GIST arising from the liver in a long‑term survivor of anorectal melanoma. The patient underwent APR for treatment of malignant melanoma of the anorectum in 2001 with no adjuvant therapy and remained disease-free until 2009. In 2009, the patient presented with a solitary, rapidly growing hypervascular liver tumor, which was subsequently diagnosed as a primary GIST of the liver. Imatinib treatment (400 mg/day) was initially administered for two months, however, disease progression occurred. Therefore, the patient underwent chemotherapy with doxorubicin (50 mg/m2) and cisplatin (50 mg/m2) every three weeks. Although this temporarily resulted in stable disease, progression occurred five months later. Finally, oral sunitinib (37.5 mg/day) was administered; however, the patient succumbed to the disease one month later. Despite the current GIST patient exhibiting a poor response to imatinib, the present study highlights the importance of considering a second primary malignancy and performing immunohistochemical analysis upon the occurrence of a newly developed lesions in long‑term remission cancer survivors.
View References
|
1
|
Weinstock MA: Epidemiology and prognosis
of anorectal melanoma. Gastroenterology. 104:174–178.
1993.PubMed/NCBI
|
|
2
|
Yeh JJ, Shia J, Hwu WJ, et al: The role of
abdominoperineal resection as surgical therapy for anorectal
melanoma. Ann Surg. 244:1012–1017. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Homsi J and Garrett C: Melanoma of the
anal canal: a case series. Dis Colon Rectum. 50:1004–1010. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Aytac B, Adim SB, Yerci O and Yilmazlar T:
Anorectal malignant melanomas: experience of Uludag University.
Kaohsiung J Med Sci. 26:658–662. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ho MY and Blanke CD: Gastrointestinal
stromal tumors: disease and treatment update. Gastroenterology.
140:1372–1376.e2. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Reith JD, Goldblum JR, Lyles RH and Weiss
SW: Extragastrointestinal (soft tissue) stromal tumors: an analysis
of 48 cases with emphasis on histologic predictors of outcome. Mod
Pathol. 13:577–585. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hu X, Forster J and Damjanov I: Primary
malignant gastrointestinal stromal tumor of the liver. Arch Pathol
Lab Med. 127:1606–1608. 2003.PubMed/NCBI
|
|
8
|
DeChiara A, De Rosa V, Lastoria S, et al:
Primary gastrointestinal stromal tumor of the liver with lung
metastases successfully treated with STI-571 (imatinib mesylate).
Front Biosci. 11:498–501. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ochiai T, Sonoyama T, Kikuchi S, et al:
Primary large gastrointestinal stromal tumor of the liver: report
of a case. Surg Today. 39:633–636. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luo XL, Liu D, Yang JJ, Zheng MW, Zhang J
and Zhou XD: Primary gastrointestinal stromal tumor of the liver: a
case report. World J Gastroenterol. 15:3704–3707. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yamamoto H, Miyamoto Y, Nishihara Y, et
al: Primary gastrointestinal stromal tumor of the liver with PDGFRA
gene mutation. Hum Pathol. 41:605–609. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Corless CL, Fletcher JA and Heinrich MC:
Biology of gastrointestinal stromal tumors. J Clin Oncol.
22:3813–3825. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Park SH, Kim MK, Kim H, et al:
Ultrastructural studies of gastrointestinal stromal tumors. J
Korean Med Sci. 19:234–244. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Balch CM, Buzaid AC, Soong SJ, et al:
Final version of the American Joint Committee on Cancer staging
system for cutaneous melanoma. J Clin Oncol. 19:3635–3648.
2001.PubMed/NCBI
|
|
15
|
Heinrich MC, Owzar K, Corless CL, et al:
Correlation of kinase genotype and clinical outcome in the North
American Intergroup Phase III Trial of imatinib mesylate for
treatment of advanced gastrointestinal stromal tumor: CALGB 150105
Study by Cancer and Leukemia Group B and Southwest Oncology Group.
J Clin Oncol. 26:5360–5367. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yeh CN, Chen TW, Lee HL, et al: Kinase
mutations and imatinib mesylate response for 64 Taiwanese with
advanced GIST: preliminary experience from Chang Gung Memorial
Hospital. Ann Surg Oncol. 14:1123–1128. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim TW, Ryu MH, Lee H, et al: Kinase
mutations and efficacy of imatinib in Korean patients with advanced
gastrointestinal stromal tumors. Oncologist. 14:540–547. 2009.
View Article : Google Scholar : PubMed/NCBI
|
